A prospective comparative study of [68Ga]Ga-RM26 and [68Ga]Ga-PSMA-617 PET/CT imaging in suspicious prostate cancer
European Journal of Nuclear Medicine and Molecular Imaging · 2023-06 · 50 (7) · 2177-2187
DOI: 10.1007/s00259-023-06142-2 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Nuclear Medicine and Molecular Imaging, online erschienen am 22.02.2023. Verfasst von Xiaomei Gao und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, Disorders of Prostate Cancer Multidisciplinary Team, National Clinical Research Center for Geriatric Disorders, Xiangya Hosp…. Hauptthemen laut MEDLINE: Prostate-Specific Antigen, Prostatic Neoplasms. Die Arbeit wurde bisher 26-mal zitiert (Crossref) und nennt 57 Literaturangaben. Gefördert von: National Natural Science Foundation of China, the Science and Technology Innovation Program of Hunan Province, the Key Research and Development Program of Hunan Province.
Abstract (Originalsprache)
PURPOSE: Prostate-specific membrane antigen (PSMA)-based PET/CT imaging has limitations in the diagnosis of prostate cancer (PCa). We recruited 207 participants with suspicious PCa to perform PET/CT imaging with radiolabeled gastrin-releasing peptide receptor (GRPR) antagonist, [68Ga]Ga-RM26, and compare with [68Ga]Ga-PSMA-617 and histopathology. METHODS: Every participant with suspicious PCa was scanned with both [68Ga]Ga-RM26 and [68Ga]Ga-PSMA-617 PET/CT. PET/CT imaging was compared using pathologic specimens as a reference standard. RESULTS: Of the 207 participants analyzed, 125 had cancer, and 82 were diagnosed with benign prostatic hyperplasia (BPH). The sensitivity and specificity of [68Ga]Ga-RM26 and [68Ga]Ga-PSMA-617 PET/CT imaging differed significantly for detecting clinically significant PCa. The area under the ROC curve (AUC) was 0.54 for [68Ga]Ga-RM26 PET/CT and 0.91 for [68Ga]Ga-PSMA-617 PET/CT in detecting PCa. For clinically significant PCa imaging, the AUCs were 0.51 vs. 0.93, respectively. [68Ga]Ga-RM26 PET/CT imaging had higher sensitivity for PCa with Gleason score (GS) = 6 (p = 0.03) than [68Ga]Ga-PSMA-617 PET/CT but poor specificity (20.73%). In the group with PSA < 10 ng/mL, the sensitivity, specificity, and AUC of [68Ga]Ga-RM26 PET/CT were lower than [68Ga]Ga-PSMA-617 PET/CT (60.00% vs. 80.30%, p = 0.12, 23.26% vs. 88.37%, p = 0.000, and 0.524 vs. 0.822, p = 0.000, respectively). [68Ga]Ga-RM26 PET/CT exhibited significantly higher SUVmax in specimens with GS = 6 (p = 0.04) and in the low-risk group (p = 0.01), and its uptake did not increase with PSA level, GS, or clinical stage. CONCLUSION: This prospective study provided evidence for the superior accuracy of [68Ga]Ga-PSMA-617 PET/CT over [68Ga]Ga-RM26 PET/CT in detecting more clinically significant PCa. [68Ga]Ga-RM26 PET/CT showed an advantage for imaging low-risk PCa.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pathology, Disorders of Prostate Cancer Multidisciplinary Team, National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Hunan Province, No.87 Xiangya Road, Ch…
- Department of Nuclear Medicine, Disorders of Prostate Cancer Multidisciplinary Team, National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Hunan Province, No.87 Xiangya R…
- Department of Urology, Disorders of Prostate Cancer Multidisciplinary Team, National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Hunan Province, No.87 Xiangya Road, Chan…
- Key Laboratory of Biological, Nanotechnology of National Health Commission, Xiangya Hospital, Central South University, Hunan Province, No.87 Xiangya Road, Changsha City, 410008, People's Republic of China. hushuo2018@1…
ORCID-Profile: Yi Cai
Förderung
- National Natural Science Foundation of China
- the Science and Technology Innovation Program of Hunan Province
- the Key Research and Development Program of Hunan Province
- Natural Science Foundation of Hunan Province
- the Clinical Research Fund Project of National Geriatric Disease Clinical Research Center
Zitieren
APA
Gao, X., Tang, Y., Chen, M., Li, J., Yin, H., Gan, Y., Zu, X., Cai, Y., & Hu, S. (2023). A prospective comparative study of [68Ga]Ga-RM26 and [68Ga]Ga-PSMA-617 PET/CT imaging in suspicious prostate cancer. European Journal of Nuclear Medicine and Molecular Imaging, 50(7), 2177-2187. https://doi.org/10.1007/s00259-023-06142-2
Vancouver
Gao X, Tang Y, Chen M, Li J, Yin H, Gan Y, et al. A prospective comparative study of [68Ga]Ga-RM26 and [68Ga]Ga-PSMA-617 PET/CT imaging in suspicious prostate cancer. European Journal of Nuclear Medicine and Molecular Imaging. 2023;50(7):2177-2187. doi:10.1007/s00259-023-06142-2
BibTeX
@article{Gao2023,
author = {Gao, Xiaomei and Tang, Yongxiang and Chen, Minfeng and Li, Jian and Yin, Hongling and Gan, Yu and Zu, Xiongbin and Cai, Yi and Hu, Shuo},
title = {A prospective comparative study of [68Ga]Ga-RM26 and [68Ga]Ga-PSMA-617 PET/CT imaging in suspicious prostate cancer},
journal = {European Journal of Nuclear Medicine and Molecular Imaging},
year = {2023},
volume = {50},
number = {7},
pages = {2177--2187},
doi = {10.1007/s00259-023-06142-2}
}
EUVIMED